お知らせ • Jul 09
The Craneware Group Introduces Medication Reimbursement Intelligence The Craneware Group introduced Medication Reimbursement Intelligence, its strategic framework for helping health systems manage medication reimbursement as a connected financial system. Medication reimbursement is changing. Evolving 340B reimbursement models, Medicare drug pricing requirements, third-party validation platforms, and increasing post-adjudication complexity are reshaping how medication revenue is validated, reconciled, and ultimately realized. What was once managed through a series of largely independent workflows has become a connected financial process that unfolds over time. Healthcare is entering an era where medication reimbursement must be managed as a financial system — not simply a series of reimbursement events. Drawing on decades of experience helping more than 2,000 hospitals and health systems improve financial performance, The Craneware Group has observed a fundamental shift in how medication reimbursement is managed. Health systems are being asked to navigate more reimbursement models, more validation requirements, and more financial dependencies than ever before. Many organizations have responded by adding workflows, tools, and staff. While necessary, those approaches often increase fragmentation across systems, teams, and timelines — limiting financial visibility, increasing audit exposure, and making it more difficult to understand financial performance across the reimbursement process. The pace of change across medication reimbursement now warrants a common framework for understanding and managing this growing complexity. Medication Reimbursement Intelligence is The Craneware Group's strategic framework for managing medication reimbursement as a connected financial system. Rather than responding to each new reimbursement requirement independently, Medication Reimbursement Intelligence brings together validation, submission, reconciliation, financial oversight, and evolving reimbursement models into a more integrated approach to financial management. It reflects how The Craneware Group believes health systems will increasingly need to manage medication reimbursement as reimbursement models continue to evolve. The Craneware Group is advancing Medication Reimbursement Intelligence through the continued development of Trisus OneLink - Medication, an evolving capability within the Trisus platform. Designed to support emerging reimbursement requirements, Trisus OneLink - Medication reflects The Craneware Group's commitment to helping health systems manage medication reimbursement through a more connected financial approach. The Craneware Group will continue the conversation during the 340B Coalition Summer Conference, where the company will engage healthcare leaders on the future of medication reimbursement and share how its ongoing investments are helping shape this emerging approach. お知らせ • Jul 03
Craneware plc Provides Earnings Guidance for the Year Ended 30 June 2026 Craneware plc provided earnings guidance for the year ended 30 June 2026. The Board expects the Group's FY26 financial performance to be below market expectations, with revenue of USD 205 million - USD 208 million, broadly in line with FY25. This change results from the timing of eligible 340 B activity and the deferral of a small number of significant enterprise contracts, which are now expected to contribute during FY27. The final reported outcome remains subject to confirmation of eligible 340B activity recognised before the financial year end. The Group recognises a significant proportion of this revenue upon the customer receiving the benefit from these eligible 340B drugs, rather than at the point opportunities are identified. The financial impact of this reduced conversion only became apparent once the actual amount of 340B drugs shipped to the hospitals before year end became clear. お知らせ • Mar 03
Craneware plc Declares Interim Dividend for the Six Months Ended 31 December 2025, Payable on 16 April 2026 Craneware plc announced the board has declared an interim dividend of 15.0 pence per ordinary share (20.25 cents per ordinary share) for the six months ended 31 December 2025 (H1 FY25: 13.5 pence per ordinary share (16.87 cents per ordinary share)). The interim dividend is payable on 16 April 2026 to those shareholders on the register as at 20 March 2026. The ex-dividend date is 19 March 2026. The interim dividend of 15 pence per share is capable of being paid in US dollars subject to a shareholder having registered to receive their dividend in US dollars under the Company's Dividend Currency Election, or who has registered to do so by the close of business on 20 March 2026. The exact amount to be paid will be calculated by reference to the exchange rate to be announced on 20 March 2026. お知らせ • Jan 20
Craneware plc to Report First Half, 2026 Results on Mar 02, 2026 Craneware plc announced that they will report first half, 2026 results on Mar 02, 2026 お知らせ • Nov 22
Craneware plc Announces Board Changes As previously announced, following many years of service on the Board of Directors, David Kemp, Senior Non-Executive Director, has decided not to stand for re-election at the Company's AGM later 21 November 2025 and as a result, will retire from the Board following the close of the meeting. The Board thanks him for his significant contributions during his tenure. His insight and constructive challenge have been invaluable, helping drive Craneware's success. Following the completion of the AGM, Alistair Erskine will assume the role of Senior Independent Director, Susan Nelson will assume the role of Chair of the Audit Committee and Jill Goldsmith will take over the role of Company Secretary to the Board. お知らせ • Sep 16
Craneware plc Recommends Final Dividend for the Year Ended 30 June 2025, Payable on 18 December 2025 Craneware plc recommended final dividend for the year ended 30 June 2025 of 18.5 pence per share (FY24: 16.0 pence per share), resulting in a proposed total dividend for the year of 32.0 pence per share (FY24: 29 pence per share). Subject to shareholder approval at the Annual General Meeting, the final dividend is expected to be paid on 18 December 2025 to those on the register as at 28 November 2025, with the corresponding ex-dividend date of 27 November 2025. The final dividend of 18.5 pence per share is capable of being paid in US dollars subject to a shareholder having registered to receive their dividend in US dollars under the Company's Dividend Currency Election, or who register to do so by the close of business on 28 November 2025. The exact amount to be paid will be calculated by reference to the exchange rate to be announced on 28 November 2025. お知らせ • Jul 16
Craneware plc to Report Fiscal Year 2025 Results on Sep 15, 2025 Craneware plc announced that they will report fiscal year 2025 results on Sep 15, 2025 お知らせ • Jun 12
Bain Capital Intends Not to Make an Offer for Craneware Further to the announcement on 16 May 2025 regarding a possible offer for Craneware plc (AIM:CRW) ("Craneware"), Bain Capital Private Equity (Europe), LLP ("Bain Capital"), in its capacity as an adviser to the funds managed and/or advised by it or its affiliates (the "Bain Capital Funds"), confirmed that it does not intend to make a firm offer for Craneware. This is a statement to which Rule 2.8 of the Code applies. Accordingly, Bain Capital and any person(s) acting in concert with it will, except with the consent of the Panel on Takeovers and Mergers (the "Takeover Panel"), be bound by the restrictions set out in Rule 2.8 of the Code. Under Note 2 of Rule 2.8 of the Code, Bain Capital, and any person(s) acting in concert with it, reserves the right to set the restrictions in Rule 2.8 of the Code aside in the following circumstances: a) with the agreement of the Board of Directors of Craneware; b) following the announcement of a firm intention to make an offer for Craneware by, or on behalf of, a third party; c) following the announcement by Craneware of a Rule 9 waiver proposal (as described in Note 1 of the Notes on Dispensations from Rule 9 of the Code), or a reverse takeover (as defined by the Code); or d) where the Takeover Panel has determined that there has been a material change in circumstances. Bain Capital also reserves the right to acquire shares of Craneware, subject to, and in accordance with, the Code and other applicable regulations. お知らせ • Jun 11
Bain Capital Private Equity (Europe), LLP cancelled the acquisition of Craneware plc (AIM:CRW). Bain Capital Private Equity (Europe), LLP proposed to acquire Craneware plc (AIM:CRW) for approximately £940 million on May 16, 2025. Bain Capital confirms that the Bain Capital Funds are assessing a possible offer to acquire the issued and to be issued share capital of Craneware. This evaluation is highly preliminary in nature, and has not to date involved any approach to the Board of Craneware. The Board of Craneware confirms that no proposal has been received from Bain Capital.
Khamran Ali and Nick Harper of Goldman Sachs International acted as financial advisor for Craneware plc. Neil Patel, Michael Nicholson, Benjamin Cryer and Kate Bannatyne of Peel Hunt LLP acted as financial advisor for Craneware plc.
Bain Capital Private Equity (Europe), LLP cancelled the acquisition of Craneware plc (AIM:CRW) on June 11, 2025. The Board confirms that it rejected a proposal from Bain Capital that valued Craneware at £26.50 per share, a price which the Board believes fundamentally undervalues Craneware and its prospects. The proposal was received without the parties entering into a due diligence process. The Board believes that the proposal received from Bain is not in the best interest of shareholders and is not consistent with the Board's understanding of the objectives of shareholders. The Board believes the Company's share price performance over the last 12 months is not reflective of the Company's trading performance and the continued improving prospects of the business, instead reflecting non-Craneware specific market factors. Bain Capital Private Equity (Europe), LLP also confirms that it does not intend to make a firm offer for Craneware. お知らせ • Mar 12
Craneware plc Declares an Interim Dividend, Payable on 17 April 2025 The Board of Craneware plc has declared an interim dividend of 13.5 pence (16.87 cents) per ordinary share, payable on 17 April 2025 to those shareholders on the register as at 21 March 2025 (FY24 Interim dividend 13.0 pence). The ex-dividend date is 20 March 2025. The interim dividend of 13.5 pence per share is capable of being paid in US dollars subject to a shareholder having registered to receive their dividend in US dollars under the Company's Dividend Currency Election, or who has registered to do so by the close of business on 21 March 2025. The exact amount to be paid will be calculated by reference to the exchange rate to be announced on 21 March 2025. The interim dividend referred to above in US dollars of 16.87 cents is given as an example only using the Balance Sheet date exchange rate of $1.25/£1 and may differ from that finally announced. お知らせ • Nov 13
Craneware plc Announces Board and Committee Changes Craneware plc announced, following many years' service on the Board of Directors, Colleen Blye, Senior Non-Executive Director, and Russ Rudish, Non-Executive Director, are not standing for re-election at the Company's AGM later on 13 November 2024. The company announced the appointment of Tamra Minnier as Non-Executive Director, which will take effect following 13 November 2024 AGM. Tamra is an experienced senior US healthcare executive, currently holding the role of Senior Vice President, Health Services Division, and Chief Quality and Operational Excellence Officer for UPMC. Tamra's role includes overseeing the Wolff Center, the driving force for Quality and Safety, Nursing, Surgical Services, Pharmacy, Imaging and Laboratory Operations for UPMC and responsibility for The Beckwith Institute. Following the completion of the AGM, David Kemp, will assume the role of Senior Independent Director, as well as continuing his role as Chair of the Audit Committee; Alistair Erskine will assume the role of Chair of the Remuneration Committee, and the appointment of Tamra Minnier will come into effect. Tamra E. Minnier, aged 62, has been a director or partner of the following companies or partnerships during the five years preceding the date of this announcement: Current: The United Way of Southwestern Pennsylvania; Phipps Conservatory and Botanical Gardens Inc.; Aging Institute; Infectious Disease Connect Inc. and The United Way of Western Pennsylvania. Historic: Joint Commission Resources Inc. and Patient Safety Movement Foundation. お知らせ • Oct 18
Craneware plc, Annual General Meeting, Nov 13, 2024 Craneware plc, Annual General Meeting, Nov 13, 2024. Location: the offices of craneware plc, 1 tanfield, eh3 5da, edinburgh United Kingdom お知らせ • Jul 18
Craneware plc to Report Fiscal Year 2024 Results on Sep 03, 2024 Craneware plc announced that they will report fiscal year 2024 results on Sep 03, 2024 お知らせ • Mar 05
Craneware plc Declares Dividend, Payable on April 15, 2024 The Board of Craneware plc declared a dividend of 13.0 pence (16.51 cents) per ordinary share, payable on 15 April 2024 to those shareholders on the register as at 22 March 2024 (Fiscal year 2023 Interim dividend 12.5 pence). The ex-dividend date is 21 March 2024. The interim dividend of 13.0 pence per share is capable of being paid in US dollars subject to a shareholder having registered to receive their dividend in US dollars under the Company's Dividend Currency Election, or who has registered to do so by the close of business on 22 March 2024. The exact amount to be paid will be calculated by reference to the exchange rate to be announced on 22 March 2024. The interim dividend referred to above in US dollars of 16.51 cents is given as an example only using the Balance Sheet date exchange rate of $1.27/£1 and may differ from that finally announced. お知らせ • Jan 17
Craneware plc to Report First Half, 2024 Results on Mar 04, 2024 Craneware plc announced that they will report first half, 2024 results on Mar 04, 2024 お知らせ • Oct 18
Craneware plc, Annual General Meeting, Nov 16, 2023 Craneware plc, Annual General Meeting, Nov 16, 2023, at 10:00 Coordinated Universal Time. Location: offices of Craneware plc 1 Tanfield Edinburg United Kingdom Agenda: To receive and consider the Company's 2023 annual accounts and the Directors' and Auditors' reports; to approve the Directors' Remuneration Report; to re-appoint William Whitehorn as a Director; to re-appoint Keith Neilson as a Director; to re-appoint Craig Preston as a Director; to re-appoint Isabel Urquhart as a Director; to re-appoint Colleen Blye as a Director; to re-appoint Russ Rudish as a Director; to re-appoint Alistair Erskine as a Director; to re-appoint David Kemp as a Director; to re-appoint Anne McCune as a Director; to declare a final dividend of 16.0 pence per share, giving a total dividend for the year of 28.5 pence per share; to re-appoint PricewaterhouseCoopers LLP as the auditors of the Company and to authorise the directors to fix their remuneration; to authorise the directors to allot unissued ordinary shares; and to consider other matters. お知らせ • Sep 05
Craneware plc Proposes Final Dividend for the Year Ended 30 June 2023, Payable on 15 December 2023 Craneware plc proposed the Board proposes a final dividend of 16.0 pence (20.19 cents) per share giving a total dividend for the year of 28.5 pence (35.95 cents) per share (FY22: 28 pence (33.96 cents) per share), an increase of 2%. Subject to approval at the Annual General Meeting, the final dividend will be paid on 15 December 2023 to shareholders on the register as at 24 November 2023, with a corresponding ex-Dividend date of 23 November 2023. お知らせ • Jul 17
Craneware plc to Report Fiscal Year 2023 Results on Sep 05, 2023 Craneware plc announced that they will report fiscal year 2023 results on Sep 05, 2023